How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000

Medical Journal of Australia

Volumn 189, Issue 6, 2008, Pages 319-322

  Chen, Lei ^a   Rogers, Sophie L ^b   Colagiuri, Stephen ^c   Cadilhac, Dominique A ^d   Mathew, Timothy H ^e   Boyden, Andrew N ^f   Peeters, Anna ^a   Magliano, Dianna J ^g   Shaw, Jonathan E ^g   Zimmet, Paul Z ^g   Tonkin, Andrew M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e Kidney Health Australia   (Australia)

^f NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METABOLIC SYNDROME X; NEW ZEALAND; PRACTICE GUIDELINE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 53549109135     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb02049.x     Document Type: Article

References (18)

1. Australian Bureau of Statistics. National Health Survey: summary of results, 2004-05. Canberra: ABS, 2006. (ABS Cat. No. 4364.0.) http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/ 4364.02004-05?OpenDocument (accessed Jul 2008).
2. Australian Bureau of Statistics. Causes of death, Australia, 2005. Canberra: ABS, 2007. (ABS Cat. No. 3303.0.) http://www.abs.gov.au/ AUSSTATS/abs@.nsf/DetailsPage/3303.02005?OpenDocument (accessed Jul 2008).
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
4. Murray CJL, Lauer JA, Hutubessy RCW, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003; 361: 717-725.
5. Tonkin A, Barter P, Best J, et al; National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Position statement on lipid management - 2005. Heart Lung Circ 2005; 14: 275-291.
6. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 Suppl 5: v1-v52.
7. New Zealand Guidelines Group. Best practice evidence-based guideline: the assessment and management of cardiovascular risk. Wellington: NZGG, 2003. http://www.nzgg.org.nz/guidelines/0035/CVD_Risk_Full.pdf (accessed Jul 2008).
8. Australian Government Department of Health and Ageing. PBS-eligibility criteria for lipid lowering drugs: fact sheet. Canberra: DHA, 2006. http://www.health.gov.au/internet/main/publishing.nsf/content/ lipid_eligibilitycriteria.htm (accessed Jul 2008).
9. Dunstan DW, Zimmet PZ, Welborn TA, et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) - methods and response rates. Diabetes Res Clin Pract 2002; 57: 119-129.
10. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298.
11. Rose GA, Blackburn H. Cardiovascular survey methods. Geneva: World Health Organization, 1968.
12. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-1062.
13. Australian Bureau of Statistics. Population by age and sex, Australian states and territories, Jun 1997 to Jun 2002. Canberra: ABS, 2003. (ABS Cat. No. 3201.0.) http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/ 3201.0Jun%201997%20to%20Jun%202002?Open Document (accessed Jul 2008).
14. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002; 324: 1570-1576.
15. Forge BH, Briganti EM. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines? Med J Aust 2001; 175: 471-475.
16. Knuiman MW, Vu HT. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. J Epidemiol Community Health 1997; 51: 515-519.
17. Simons LA, Simons J, Friedlander Y, et al. Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. Med J Aust 2003; 178: 113-116.
18. Knuiman MW, Vu HT, Bartholomew HC. Multivariate risk estimation for coronary heart disease: the Buselton Health Study. Aust N Z J Public Health 1998; 22: 747-753.